Keyphrases
Cerebral Blood Flow
100%
Healthy Volunteers
38%
Perfusion
36%
Cerebral Oxygenation
35%
Glutamate
33%
Magnetic Resonance Spectroscopy
31%
Positron Emission Tomography
30%
Magnetic Resonance Imaging
30%
Migraine without Aura (MWoA)
28%
CMRO2
27%
Meningioma
25%
Lactate
25%
15O-H2O
25%
Hypoxia
24%
Phase Contrast
24%
Healthy Controls
23%
Proton Magnetic Resonance Spectroscopy
21%
Cerebral Perfusion
20%
Magnetic Resonance Imaging Techniques
19%
N-acetylaspartate
18%
Migraine
18%
Inhalation
18%
Pons
17%
Spectroscopy Studies
16%
Blood-brain Barrier Permeability
16%
Cerebrovascular Reactivity
16%
Arterial Spin Labeling
16%
Hypoxic Exposure
15%
Oxygen Metabolism
15%
Lactate Level
14%
Arterial Input Function
14%
Cerebrospinal Fluid Lactate
14%
Multiple Sclerosis
13%
Capillary Transit Time Heterogeneity
13%
Functional Magnetic Resonance Imaging
13%
High-resolution Magnetic Resonance Imaging (HRMRI)
13%
Somatostatin Receptor 2 (SSTR2)
13%
Magnetic Resonance Imaging Study
13%
18F-fluorothymidine
13%
Alzheimer's Disease
13%
Cerebral Metabolism
13%
Perfusion MRI
13%
Cognitive Deficits
13%
PET Imaging
13%
Albuminuria
13%
Cerebral Atrophy
13%
Visual Stimulation
12%
Relapsing-remitting multiple Sclerosis
12%
Regional Cerebral Blood Flow (rCBF)
12%
Brain Atrophy
11%
Neuroscience
Magnetic Resonance Imaging
77%
Magnetic Resonance Imaging
60%
Nuclear Magnetic Resonance Spectroscopy
57%
Metabolic Pathway
53%
Positron Emission Tomography
46%
Migraine
42%
Glutamic Acid
37%
Meningioma
27%
Auras
25%
Positron Emission Tomography
24%
Fluorine-18
22%
In Vivo
21%
Blood Brain Barrier
17%
Thalamus
16%
Pons
16%
Arterial Spin Labeling
16%
Functional Magnetic Resonance Imaging
15%
Brain Metabolism
15%
Alzheimer's Disease
13%
Cognitive Disorders
13%
Multiple Sclerosis
13%
Relapsing Remitting Multiple Sclerosis
13%
Carbon Monoxide
13%
Receptor Subtype
13%
Somatostatin Receptor
13%
Gray Matter
11%
Headache
10%
Brain Function
10%
Acetazolamide
10%
Visual Cortex
9%
Neurodegenerative Disorder
9%
Gamma-Aminobutyric Acid
9%
Placebo
9%
Positron Emission Tomography-Computed Tomography
9%
Oxygen Saturation
8%
Aura (Symptom)
8%
Superior Sagittal Sinus
8%
Glutamine
8%
Creatine Phosphate
7%
Calcitonin
7%
Sildenafil
7%
Cell Proliferation
7%
Hippocampus
6%
Randomized Controlled Trial
6%
Erythropoietin
6%
Propofol
6%
Amyloid
6%
Obstructive Sleep Apnea
6%
Alemtuzumab
6%
Neurovascular Coupling
6%
Medicine and Dentistry
Magnetic Resonance Imaging
43%
Positron Emission Tomography
35%
Brain Blood Flow
31%
Meningioma
27%
Volunteer
20%
Disease
18%
Positron Emission Tomography
17%
Fluorine-18
17%
Functional Magnetic Resonance Imaging
14%
Capillary
14%
Migraine with Aura
13%
Somatostatin Receptor
13%
Receptor Subtype
13%
Blood Oxygenation
12%
Gallium 68
11%
Placebo
10%
Brain Perfusion
10%
Radioactive Tracer
9%
Migraine
9%
Hypoxia
9%
Positron Emission Tomography-Computed Tomography
9%
Aura (Symptom)
9%
Oxygen 15
8%
Tetraxetan
8%
Tumor Progression
7%
Cell Proliferation
7%
Visual Cortex
7%
Auras
6%
Telomere
6%
Autophagy
6%
Supplementation
6%
Pharmacokinetics
6%
Migraine without Aura
6%
Cellular Senescence
6%
Stem Cell
6%
Kidney Parenchyma
6%
Randomized Controlled Trial
6%
Cell Communication
6%
Nerve Cell Differentiation
6%
Glucagon Like Peptide 1
6%
Microbiome
6%
Nutrient Sensing
6%
Protein Homeostasis
6%
Genomic Instability
6%
Carbon Monoxide
6%
Brain Capillary
6%
Headache
6%
Multiple Sclerosis
6%
Oxygen Consumption
6%
Ezetimibe
6%
